Oct 2026· International Journal of Molecular Sciences· Vol 27, pp. 9221· 0 citations· 48 references
Medicine
TL;DR
Findings support plasma miRNA profiles as potential MACE biomarkers and all DE miRNAs remain exploratory, although further studies in larger independent populations with cross-validation are required before integration with traditional risk markers to predict future MACE.
Abstract
Circulating microRNAs (miRNAs) are promising biomarkers of cardiovascular disease (CVD) and three-point major adverse cardiovascular events (3P-MACE): CVD death, non-fatal myocardial infarction (MI), and non-fatal stroke. The associations between plasma miRNA levels and 3P-MACE in a prospective cohort from an epidemiological study were evaluated. This nested case–control study included 479 participants: 166 cases with 3P-MACE and 313 controls matched individually for sex, exact baseline age, and region of residence. Median follow-up was 10.4 years [7.0; 11.7]. Total RNA was isolated from EDTA plasma using the miRNeasy Serum/Plasma Advanced Kit. Libraries were prepared with the QIAseq miRNA UDI Library Kit and sequenced on a NextSeq 550 (1 × 75 bp). After adjustment for six and twelve preanalytical and clinical covariates, eleven and five differentially expressed (DE) miRNAs retained significant associations with 3P-MACE or CVD death, respectively. Although these findings support plasma miRNA profiles as potential MACE biomarkers, all DE miRNAs remain exploratory. Further studies in larger independent populations with cross-validation are required before integration with traditional risk markers to predict future MACE.
Elevated levels of cardiorenal-inflammatory markers reflect not only risk of cardiovascular disease (CVD), but also of cancer. The objectives of the current study were to examine whether N-terminal pro-B-type natriuretic peptide (NT-proBNP), urinary albumin excretion (UAE) and high-sensitivity C reactive protein...
Y. Yang, T.-F. Kok, M. Maronier et al.· European Heart Journal· 0 citations
AIMS
To determine how high-sensitivity C-reactive protein (hsCRP) and lipoprotein(a) [Lp(a)] predict major adverse cardiovascular events (MACE) across the spectrum of baseline cardiovascular risk.
METHODS
UK Biobank participants were grouped according to baseline cardiovascular risk. The primary endpoint was first MA...
B. Tucker, Leung-Ong Kwok, Thomas Payne et al.· Atherosclerosis· 0 citations
Introduction:
MicroRNAs are emerging biomarkers involved in the regulation of endothelial function andatherosclerotic plaque progression. MicroRNA-92a (miR-92a) downregulates Kruppel-likefactor 2 (KLF2), a key mediator of endothelial homeostasis and atheroprotection.Although elevated miR-92a expression has been link...
Maria Przezdziecka, M. Kowara, Agnieszka Cudnoch-Jędrzejewska· Circulation· 0 citations
Current risk stratification algorithms capture high-risk individuals with classical risk factors or established atherosclerotic cardiovascular disease (ASCVD). However, a clinically relevant proportion of individuals without threshold levels of standard modifiable risk factors (SMuRF) – namely hypertension, dysli...
F. Kahles, B. Kurt, K. Schneider et al.· European Heart Journal· 0 citations
Background Frailty predicts adverse health outcomes, but its relationship with cardiovascular disease (CVD) requires further validation across diverse populations. The value of a circulating protein signature for cardiovascular risk assessment remains uncertain. Methods We examined frailty–CVD associations in the XiDu2...
Ping-Jing Zheng, Jia-Bo Wu, Xiao-Qing Gu et al.· International Journal of Car...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.